Saltz L - Search Results

1

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

Franko J, Shi Q, Meyers JP, Maughan TS, Adams RA, Seymour MT, Saltz L, Punt CJA, Koopman M, Tournigand C, Tebbutt NC, Diaz-Rubio E, Souglakos J, Falcone A, Chibaudel B, Heinemann V, Moen J, De Gramont A, Sargent DJ, Grothey A; Analysis and Research in Cancers of the Digestive System (ARCAD) Group. Franko J, et al. Among authors: saltz l. Lancet Oncol. 2016 Dec;17(12):1709-1719. doi: 10.1016/S1470-2045(16)30500-9. Epub 2016 Oct 12. Lancet Oncol. 2016. PMID: 27743922 Free article. Clinical Trial.

2

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, Sun M, Pulliam S, Gonzalez C. Conti JA, et al. Among authors: saltz lb. J Clin Oncol. 1996 Mar;14(3):709-15. doi: 10.1200/JCO.1996.14.3.709. J Clin Oncol. 1996. PMID: 8622015

3

Irinotecan in the first-line treatment of colorectal cancer.

Saltz LB. Saltz LB. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):54-8. Oncology (Williston Park). 1998. PMID: 9726092 Review.

4

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL. Saltz LB, et al. N Engl J Med. 2000 Sep 28;343(13):905-14. doi: 10.1056/NEJM200009283431302. N Engl J Med. 2000. PMID: 11006366 Free article. Clinical Trial.

5

The role of irinotecan in colorectal cancer.

Saltz LB. Saltz LB. Curr Oncol Rep. 1999;1(2):155-60. doi: 10.1007/s11912-999-0027-1. Curr Oncol Rep. 1999. PMID: 11122813 Review.

6

Surgical debulking and intraperitoneal chemotherapy for established peritoneal metastases from colon and appendix cancer.

Culliford AT 4th, Brooks AD, Sharma S, Saltz LB, Schwartz GK, O'Reilly EM, Ilson DH, Kemeny NE, Kelsen DP, Guillem JG, Wong WD, Cohen AM, Paty PB. Culliford AT 4th, et al. Among authors: saltz lb. Ann Surg Oncol. 2001 Dec;8(10):787-95. doi: 10.1007/s10434-001-0787-9. Ann Surg Oncol. 2001. PMID: 11776492

7

New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer.

Holen KD, Saltz LB. Holen KD, et al. Among authors: saltz lb. Lancet Oncol. 2001 May;2(5):290-7. doi: 10.1016/S1470-2045(00)00324-7. Lancet Oncol. 2001. PMID: 11905784 Review.

8

A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.

Sharma S, Kemeny N, Kelsen DP, Ilson D, O'Reilly E, Zaknoen S, Baum C, Statkevich P, Hollywood E, Zhu Y, Saltz LB. Sharma S, et al. Among authors: saltz lb. Ann Oncol. 2002 Jul;13(7):1067-71. doi: 10.1093/annonc/mdf173. Ann Oncol. 2002. PMID: 12176785 Free article. Clinical Trial.

9

Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer.

Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB. Schrag D, et al. Among authors: saltz l. J Clin Oncol. 2002 Oct 1;20(19):3999-4005. doi: 10.1200/JCO.2002.11.084. J Clin Oncol. 2002. PMID: 12351597

10

Radical resection of rectal cancer primary tumor provides effective local therapy in patients with stage IV disease.

Nash GM, Saltz LB, Kemeny NE, Minsky B, Sharma S, Schwartz GK, Ilson DH, O'Reilly E, Kelsen DP, Nathanson DR, Weiser M, Guillem JG, Wong WD, Cohen AM, Paty PB. Nash GM, et al. Ann Surg Oncol. 2002 Dec;9(10):954-60. doi: 10.1007/BF02574512. Ann Surg Oncol. 2002. PMID: 12464586

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

493 results

Search Page